1. Australia Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Cogstate Ltd

Cogstate Ltd

3.60
AUD
+0.02
(+0.56%)
0.10EPS
27.14P/E
463.88MMarket Cap
Feb 24Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
0.12
0.09
0.14
0.18
0.19
0.13
0.1
0.14
0.26
0.23
0.25
0.3
0.34
Basic EPS, GAAP
-0.04
-0.03
0.01
- -
- -
-0.01
-0.01
0.02
0.04
0.02
0.03
0.06
0.07
Free Cash Flow per Basic Share
-0.04
-0.03
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
Book Value per Share
0.12
0.06
0.07
0.07
0.07
0.06
0.07
0.1
0.19
0.22
0.24
0.28
0.34
Tangible Book Value per Share
0.1
0.05
0.07
0.07
0.06
0.03
0.04
0.06
0.13
0.15
0.18
0.22
0.26
Basic Weighted Avg Shares
91
100
111
114
115
119
159
170
173
173
172
171
171
Sales/Revenue/Turnover
11
9
15
21
21
15
16
25
45
40
43
51
58
Operating Margin (%)
-38.89
-26.96
2.57
-1.41
0.63
-26.8
-8.13
11.71
24.14
5.57
14.21
21.25
20.9
Depreciation Expense
1
- -
- -
1
- -
- -
1
2
2
3
3
3
3
Net Income, GAAP
-3
-3
1
- -
- -
-2
-1
4
8
4
5
10
12
Effective Tax Rate (%)
- -
- -
- -
- -
632.79
- -
- -
10.09
29.67
- -
23.26
27.06
26.17
Profit Margin (%)
-31.7
-31.49
9.69
-2.36
-1.95
-11.43
-5.56
16.01
16.72
8.82
12.55
19.97
20.38
Working Capital
7
4
5
5
4
- -
2
11
24
26
31
37
42
LT Debt
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
Total Equity
12
6
8
9
9
7
11
16
33
38
41
48
58
Return on Invested Capital (%)
- -
- -
- -
- -
-8.43
- -
- -
16
29.39
- -
11.89
17.35
16.7
Return on Capital (%)
- -
- -
- -
- -
-8.3
- -
- -
24.71
29.17
- -
13.78
22.68
22.26
Return on Common Equity (%)
-36.51
-34.12
21.52
-6.02
-4.88
-22.25
-9.96
28.58
30.53
10.11
13.87
22.84
22.41

Capital Structure

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.15%
32.64%
21.66%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-21.43%
39.02%
17.25%
Sales/Revenue/Turnover
18.09%
22.52%
14.87%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
43
2025
- -
- -
51
2026
- -
- -
58

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
0.06
2026
- -
- -
0.07

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
0.01

Company Description

Company Profile APIChatGPT
CEO
Bradley John O'Connor
Full Time Employees
160
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
161 Collins Street Melbourne VIC Australia 3000
IPO Date
Dec 12, 2003
Website
cogstate.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Cogstate Limited (ASX: CGS) is a neuroscience technology company that creates, validates, and commercializes digital brain health assessments worldwide; designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments; and offers scientific consulting, project management, data management, statistical analysis, and reporting. The company provides computerized cognitive tests across domains including Alzheimer's disease and dementia, preclinical Alzheimer's, pediatrics and rare diseases, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, sleep, and mood disorders; supports electronic clinical outcome assessment (eCOA) solutions; delivers remote assessment capabilities; and supplies healthcare cognitive screening tools alongside research and academic collaboration solutions. Founded in 1999 and headquartered in Melbourne, Australia, with key offices in New Haven, Connecticut, and London, Cogstate operates primarily in the clinical trials, healthcare, and academic research segments, serving biopharmaceutical companies, physicians, and institutions across multiple continents. In fiscal year 2025, the company reported record revenue growth of 22% driven by a 28% increase in clinical trials revenue to $50.6 million, alongside EBITDA expansion of 72%; entered a strategic partnership with Medidata in October 2024 to expand reach in central nervous system clinical research; prepared to launch its first AI-powered products in fiscal year 2026 to enhance data quality and signal detection; and declared its maiden dividend while securing $35.9 million in revenue under contract entering fiscal year 2026.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Cogstate Limited (COGZF) Q4 2026 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Discusses Clinical Trials Growth Through Indication and Solution Expansion With Focus on Psychiatry and Narcolepsy Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) FY 2025 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Q2 2025 Earnings Call Transcript

  • globenewswire.com

    Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer

  • seekingalpha.com

    Cogstate Limited (COGZF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    Cogstate Limited (COGZF) CEO Brad O'Connor on Q4 2022 Results - Earnings Call Transcript